Overcoming Chemoresistance and Activating the Immune System in Difficult-to-Treat Cancers

Episode Summary

Executive Summary: The episode examines Actuate Therapeutics’ GSK3-beta inhibitor, elraglusib, and its proposed dual action: reversing chemoresistance and stimulating anti-tumor immunity. CEO Dan Schmidt describes strong early and randomized clinical data in metastatic pancreatic cancer, a manageable safety profile, and a broader development strategy spanning injectable and oral formulations, additional tumor types, and potential partnerships.

Main Topics: GSK3-beta biology and cancer relevance (Priority: 5/5): Schmidt explains that GSK3-beta is normally involved in glucose metabolism, but in cancer it is co-opted into the nucleus and acts upstream of NF-kappa-B, supporting tumor growth, survival, and chemoresistance. Why Actuate targets GSK3-beta instead of NF-kappa-B (Priority: 5/5): The company argues that directly inhibiting NF-kappa-B is too nonspecific, while GSK3-beta offers a more druggable upstream lever to suppress the same oncogenic pathways. Elraglusib’s multimodal mechanism (Priority: 5/5): The drug is presented as more than a kinase inhibitor: it appears to reverse chemo resistance, affect DNA repair and EMT in pancreatic cancer, and increase immune recognition via neoantigen presentation and immune-cell recruitment. Clinical evidence in metastatic pancreatic cancer (Priority: 5/5): Schmidt highlights a phase 1b/2a basket study and a larger randomized phase 2 trial showing improved survival when elraglusib is added to gemcitabine/nab-paclitaxel, with limited added toxicity. Development strategy: IV and oral formulations (Priority: 3/5): Actuate is advancing both injectable and oral versions to fit current oncology practice, enable broader dosing, and support chronic or outpatient use across different tumor settings. Pipeline expansion and prioritization (Priority: 4/5): Beyond pancreatic cancer, Actuate is exploring melanoma, colorectal cancer, non-small cell lung cancer, Ewing sarcoma, and other pediatric tumors, choosing indications based on biology, clinical signal, and feasibility. Financing, commercialization, and company strategy (Priority: 3/5): The discussion closes with Actuate’s recent financing, cash runway, interest from investors, and openness to partnering or commercializing independently.

Key Arguments: GSK3-beta is not just a metabolic enzyme in normal cells; in cancer it becomes a master regulator of tumor progression and survival. Inhibiting GSK3-beta can downregulate NF-kappa-B-driven processes and help reverse chemoresistance in refractory tumors. Actuate’s compound was designed to be highly specific and potent, avoiding the broad off-target issues seen with many kinase-targeting drugs. Elraglusib shows a multimodal effect: it can sensitize tumors to chemotherapy, alter tumor cell phenotype, and stimulate immune responses. Clinical data in metastatic pancreatic cancer suggest meaningful survival improvement with a benign safety profile when elraglusib is added to gemcitabine/nab-paclitaxel. The company sees both monotherapy and combination therapy use cases depending on cancer type and biology. Actuate believes the drug could become a franchise asset and is open to partnerships, but can advance it independently if needed.

Data Points: Phase 1b/2a basket trial arms: 8 arms - Patients previously refractory to chemotherapy were rechallenged with standard therapy plus elraglusib across multiple regimens. Compounds on original pharmacophore portfolio: Over 100 - Actuate licensed a broad chemistry portfolio, from which elraglusib was selected as a highly specific candidate. Kinase-screen potency ranking: First 2 targets: GSK3 alpha and beta; next 4: FLT3, PIM, MINK, MAP kinase - Described as evidence of specificity with nearby oncogenic kinases also hit. Phase 1b/2a evaluable patients: 23 patients - Single-arm proof-of-concept pancreatic study reached a futility threshold before expanding. Median overall survival, evaluable patients: Over 15 months - First-line metastatic pancreatic cancer proof-of-concept study. Historical control median overall survival: 8.5 months - Benchmark cited for pancreatic cancer proof-of-concept comparison. Median overall survival, all enrolled patients: 11.9 months - Even using all enrolled patients, outcomes exceeded the historical control. Complete responses in proof-of-concept pancreatic study: 3 CRs in 23 patients - Noted as highly compelling relative to historical experience. Historical complete responses: 1 in 431 - Comparator cited for metastatic pancreatic cancer. Randomized phase 2 sample size: 286 patients - International first-line metastatic pancreatic cancer study. Clinical trial sites: 60 sites - Global enrollment for the randomized phase 2 study. Median overall survival in randomized study: 10.1 months vs 7.2 months - Elraglusib plus gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel control. One-year overall survival: 44% vs 22% - Doubled one-year survival in the combination arm. Control-arm survival at presentation: 10% alive - At the time of presentation, a minority of control patients remained alive versus 26% in combination. Combination-arm survival at presentation: 26% alive - At the time of the ASCO presentation. Public offering amount: $17.25 million - Actuate’s recent financing. Cash runway: Through at least the middle of next year - Estimated from current cash after the public offering. Monotherapy melanoma responders: Complete responses still living 6 years later - Small early study in refractory metastatic melanoma. Pediatric Ewing sarcoma result: First 2 patients had complete responses - Early pediatric study highlighted strong activity in refractory Ewing’s sarcoma.

Pivotal Quotes: "turning cold tumors hot" — Dan Schmidt: Describing elraglusib’s immune-activating effect through neoantigen presentation and immune-cell recruitment. "a very unique multimodal mechanisms of action agent" — Dan Schmidt: Summary of elraglusib’s combined effects on tumor biology and immune response. "the only difference between the two arms was that one got Elra and did significantly better" — Dan Schmidt: Emphasizing the randomized pancreatic cancer study’s outcome and the drug’s added benefit.

Implications: If validated in registration studies, elraglusib could become a differentiated oncology backbone therapy, especially in pancreatic cancer, with expansion into other refractory tumors. Its profile suggests value in both combination regimens and select monotherapy settings.